Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive diso… Read more
Market Cap & Net Worth: Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics, Inc. (NASDAQ:NMRA) has a market capitalization of $480.93 Million ($480.93 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13669 globally and #5622 in its home market, demonstrating a -12.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neumora Therapeutics, Inc.'s stock price $2.83 by its total outstanding shares 169938441 (169.94 Million).
Neumora Therapeutics, Inc. Market Cap History: 2023 to 2026
Neumora Therapeutics, Inc.'s market capitalization history from 2023 to 2026. Data shows change from $2.90 Billion to $480.93 Million (-51.09% CAGR).
Index Memberships
Neumora Therapeutics, Inc. is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.01% | #368 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1318 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.02% | #200 of 263 |
Weight: Neumora Therapeutics, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Neumora Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neumora Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NMRA by Market Capitalization
Companies near Neumora Therapeutics, Inc. in the global market cap rankings as of March 19, 2026.
Key companies related to Neumora Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Neumora Therapeutics, Inc. Historical Marketcap From 2023 to 2026
Between 2023 and today, Neumora Therapeutics, Inc.'s market cap moved from $2.90 Billion to $ 480.93 Million, with a yearly change of -51.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $480.93 Million | +58.10% |
| 2025 | $304.19 Million | -83.11% |
| 2024 | $1.80 Billion | -37.83% |
| 2023 | $2.90 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Neumora Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $480.93 Million USD |
| MoneyControl | $480.93 Million USD |
| MarketWatch | $480.93 Million USD |
| marketcap.company | $480.93 Million USD |
| Reuters | $480.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.